맞춤형 항체 시장 규모, 점유율, 성장, 세계 산업 분석, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of custom antibody Market

The global custom antibody market size was valued at USD 577.7 million in 2025 and is projected to grow from USD 625.7 million in 2026 to USD 1,303.4 million by 2034, registering a CAGR of 9.61% from 2026 to 2034. North America dominated the market with a 51.79% share in 2025, supported by a strong biotechnology ecosystem, advanced research capabilities, and high adoption of recombinant and engineered antibodies.

Custom antibodies are laboratory-generated antibodies developed to recognize specific antigens selected by researchers or customers. Unlike catalog antibodies, they are designed, developed, and validated for individual targets. Growing investments in biologics, antibody therapeutics, diagnostics, and research are increasing demand for specialized antibody development services.

Market Definition and Scope

The custom antibody market covers antibodies developed on demand for specific research, diagnostic, and therapeutic applications. Services include antibody design and development, production and purification, fragmentation and labeling, and other specialized services. The market is further segmented by antibody type, source, application, and end user.

Market Dynamics

Drivers

Increasing investment in biologics and antibody therapeutics is a major growth driver. Biopharmaceutical companies are expanding pipelines involving monoclonal, bispecific, recombinant, and antibody-drug conjugate technologies. This increases demand for highly specific antibodies for target identification, biomarker research, screening, and mechanism-of-action studies.

Restraints

High development costs and lengthy development timelines can restrict market expansion. Custom monoclonal antibody development may require multiple stages, including immunization, sequencing, engineering, affinity maturation, and validation, resulting in substantial time and resource requirements.

Opportunities

The expansion of recombinant and engineered antibody technologies is creating new opportunities. Recombinant antibodies provide advantages such as reproducibility, consistency, and suitability for diagnostics and research. Advances in high-throughput screening, next-generation sequencing, and AI-supported antigen design are also supporting customized antibody development.

Challenges

Regulatory complexity remains a significant challenge, particularly for therapeutic and diagnostic applications. Providers must meet stringent requirements involving documentation, quality control, manufacturing practices, and regulatory compliance, which can create additional costs and operational requirements.

Trends

Outsourcing to specialized contract research and development organizations is a major market trend. Pharmaceutical and biotechnology companies increasingly outsource antibody discovery, engineering, and production to access specialized technologies, reduce internal investment requirements, and accelerate development timelines.

Segmentation Analysis

By service, the market includes antibody design and development, antibody production and purification, antibody fragmentation and labeling, and others. Antibody production and purification held the largest market share in 2025, supported by the growing need for high-purity recombinant antibodies. Antibody fragmentation and labeling is projected to grow at a CAGR of 10.12%.

By antibody type, the market includes monoclonal antibodies, polyclonal antibodies, recombinant antibodies, and others. Monoclonal antibodies dominated in 2025 and are expected to hold a 46.7% share in 2026, supported by high specificity, consistency, scalability, regulatory acceptance, and extensive therapeutic applications. Recombinant antibodies are projected to grow at a CAGR of 11.81%.

By source, mice, rabbit, and others are covered. Mice held the leading position in 2025 and are expected to account for 54.3% in 2026 due to established workflows and widespread use in antibody discovery. The rabbit segment is projected to grow at a CAGR of 10.48%.

By application, diagnostics, therapeutics, and research are covered. Diagnostics held the leading share in 2025 and is expected to account for 39.6% in 2026, supported by demand for highly specific and reproducible antibodies. Therapeutics is projected to grow at a CAGR of 10.14%.

By end user, pharmaceutical and biotechnology companies held the largest share in 2025 and are expected to account for 37.7% in 2026. CROs and CDMOs are projected to grow at a CAGR of 12.64%.

Regional Outlook

North America led the market with a value of USD 299.2 million in 2025 and is supported by strong biotechnology and biopharmaceutical industries. The U.S. market is projected to reach USD 309.1 million in 2026, driven by R&D investment and a strong presence of CROs, CDMOs, and antibody technology providers.

Europe is projected to reach USD 161.4 million in 2026, supported by growing demand for antibody therapeutics. The U.K., Germany, and France are expected to reach USD 36.1 million, USD 33.0 million, and USD 25.9 million, respectively, in 2026.

Asia Pacific is expected to reach USD 100.1 million in 2026, making it the third-largest regional market. India and China are estimated at USD 17.8 million and USD 18.4 million, respectively, in 2026.

Latin America is projected to reach USD 24.4 million in 2026, while the GCC market in the Middle East & Africa is expected to reach USD 7.2 million.

Competitive Landscape

The market is moderately consolidated, with major life-science suppliers and specialized antibody-engineering companies competing through technology development, recombinant platforms, automation, collaborations, and expanded service portfolios. Key companies include Danaher, Thermo Fisher Scientific Inc., GenScript, Enzo Life Sciences, R&D Systems, RayBiotech, ProteoGenix, Vector Laboratories, and Sino Biological.

Recent developments include collaborations involving Spice Biotechnologies and AbTherx, BigHat Biosciences and Eli Lilly, BioNTech's acquisition of Biotheus, and strategic antibody-development partnerships involving AbbVie and Simcere Zaiming.

Report Coverage

The report covers custom antibody market size and forecast, market dynamics, trends, segmentation by service, antibody type, source, application, and end user, regional analysis, technological advancements, product development, strategic collaborations, mergers and acquisitions, competitive landscape, market share, and profiles of major market participants.

Conclusion

The global custom antibody market is projected to grow from USD 577.7 million in 2025 to USD 625.7 million in 2026 and reach USD 1,303.4 million by 2034, reflecting a 9.61% CAGR. Market expansion is supported by increasing investment in biologics, antibody therapeutics, diagnostics, and biotechnology research. North America remains the dominant regional market, while Asia Pacific continues to expand its biopharmaceutical research capabilities. Monoclonal antibodies, antibody production and purification, diagnostics, and pharmaceutical and biotechnology end users remain important market segments, while recombinant technologies, outsourcing, AI-enabled discovery, and antibody engineering are expected to influence market development through 2034.

Attribute Details

Segmentation ByService, Antibody Type, Source, Application, End User, and Region

By Service

• Antibody Design and Development
• Antibody Production & Purification
• Antibody Fragmentation & Labelling
• Others

By Antibody Type

• Monoclonal Antibodies (mAbs)
• Polyclonal Antibodies (pAbs)
• Recombinant Antibodies
• Others

By Source

• Mice
• Rabbit
• Others

By Application

• Therapeutics
• Diagnostics
• Research

By End User

• Pharmaceutical & Biotechnology Companies
• CROs & CDMOs
• Academic & Research Institutes
• Others

By Region

• North America (By Service, Antibody Type, Source, Application, End User, and Country)
• U.S.
• Canada
• Europe (By Service, Antibody Type, Source, Application, End User, and Country/Sub-region)
• Germany
• U.K.
• France
• Spain
• Italy
• Scandinavia
• Rest of Europe
• Asia Pacific (By Service, Antibody Type, Source, Application, End User, and Country/Sub-region)
• China
• Japan
• India
• Australia
• Southeast Asia
• Rest of Asia Pacific
• Latin America (By Service, Antibody Type, Source, Application, End User, and Country/Sub-region)
• Brazil
• Mexico
• Rest of Latin America
• Middle East & Africa (By Service, Antibody Type, Source, Application, End User, and Country/Sub-region)
• GCC
• South Africa
• Rest of Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Technological Advancements in Custom Antibody Manufacturing
• 4.2. Key Industry Developments - Mergers, Acquisitions, Partnerships etc.
• 4.3. New Service Launches, By Key Players
• 4.4. Regulatory Scenario, By Key Countries/Region
• 4.5. Key Start-ups in the Market

5. Global Custom Antibody Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Service
  • 5.1.1. Antibody Design and Development
  • 5.1.2. Antibody Production & Purification
  • 5.1.3. Antibody Fragmentation & Labelling
  • 5.1.4. Others
• 5.2. Market Analysis, Insights and Forecast - By Antibody Type
  • 5.2.1. Monoclonal Antibodies (mAbs)
  • 5.2.2. Polyclonal Antibodies (pAbs)
  • 5.2.3. Recombinant Antibodies
  • 5.2.4. Others
• 5.3. Market Analysis, Insights and Forecast - By Source
  • 5.3.1. Mice
  • 5.3.2. Rabbit
  • 5.3.3. Others
• 5.4. Market Analysis, Insights and Forecast - By Application
  • 5.4.1. Therapeutics
  • 5.4.2. Diagnostics
  • 5.4.3. Research
• 5.5. Market Analysis, Insights and Forecast - By End User
  • 5.5.1. Pharmaceutical & Biotechnology Companies
  • 5.5.2. CROs & CDMOs
  • 5.5.3. Academic & Research Institutes
  • 5.5.4. Others
• 5.6. Market Analysis, Insights and Forecast - Region
  • 5.6.1. North America
  • 5.6.2. Europe
  • 5.6.3. Asia Pacific
  • 5.6.4. Latin America
  • 5.6.5. Middle East & Africa

6. North America Custom Antibody Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Service
  • 6.1.1. Antibody Design and Development
  • 6.1.2. Antibody Production & Purification
  • 6.1.3. Antibody Fragmentation & Labelling
  • 6.1.4. Others
• 6.2. Market Analysis, Insights and Forecast - By Antibody Type
  • 6.2.1. Monoclonal Antibodies (mAbs)
  • 6.2.2. Polyclonal Antibodies (pAbs)
  • 6.2.3. Recombinant Antibodies
  • 6.2.4. Others
• 6.3. Market Analysis, Insights and Forecast - By Source
  • 6.3.1. Mice
  • 6.3.2. Rabbit
  • 6.3.3. Others
• 6.4. Market Analysis, Insights and Forecast - By Application
  • 6.4.1. Therapeutics
  • 6.4.2. Diagnostics
  • 6.4.3. Research
• 6.5. Market Analysis, Insights and Forecast - By End User
  • 6.5.1. Pharmaceutical & Biotechnology Companies
  • 6.5.2. CROs & CDMOs
  • 6.5.3. Academic & Research Institutes
  • 6.5.4. Others
• 6.6. Market Analysis, Insights and Forecast - By Country
  • 6.6.1. U.S.
  • 6.6.2. Canada

7. Europe Custom Antibody Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Service
  • 7.1.1. Antibody Design and Development
  • 7.1.2. Antibody Production & Purification
  • 7.1.3. Antibody Fragmentation & Labelling
  • 7.1.4. Others
• 7.2. Market Analysis, Insights and Forecast - By Antibody Type
  • 7.2.1. Monoclonal Antibodies (mAbs)
  • 7.2.2. Polyclonal Antibodies (pAbs)
  • 7.2.3. Recombinant Antibodies
  • 7.2.4. Others
• 7.3. Market Analysis, Insights and Forecast - By Source
  • 7.3.1. Mice
  • 7.3.2. Rabbit
  • 7.3.3. Others
• 7.4. Market Analysis, Insights and Forecast - By Application
  • 7.4.1. Therapeutics
  • 7.4.2. Diagnostics
  • 7.4.3. Research
• 7.5. Market Analysis, Insights and Forecast - By End User
  • 7.5.1. Pharmaceutical & Biotechnology Companies
  • 7.5.2. CROs & CDMOs
  • 7.5.3. Academic & Research Institutes
  • 7.5.4. Others
• 7.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.6.1. U.K.
  • 7.6.2. Germany
  • 7.6.3. France
  • 7.6.4. Italy
  • 7.6.5. Spain
  • 7.6.6. Scandinavia
  • 7.6.7. Rest of Europe

8. Asia Pacific Custom Antibody Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Service
  • 8.1.1. Antibody Design and Development
  • 8.1.2. Antibody Production & Purification
  • 8.1.3. Antibody Fragmentation & Labelling
  • 8.1.4. Others
• 8.2. Market Analysis, Insights and Forecast - By Antibody Type
  • 8.2.1. Monoclonal Antibodies (mAbs)
  • 8.2.2. Polyclonal Antibodies (pAbs)
  • 8.2.3. Recombinant Antibodies
  • 8.2.4. Others
• 8.3. Market Analysis, Insights and Forecast - By Source
  • 8.3.1. Mice
  • 8.3.2. Rabbit
  • 8.3.3. Others
• 8.4. Market Analysis, Insights and Forecast - By Application
  • 8.4.1. Therapeutics
  • 8.4.2. Diagnostics
  • 8.4.3. Research
• 8.5. Market Analysis, Insights and Forecast - By End User
  • 8.5.1. Pharmaceutical & Biotechnology Companies
  • 8.5.2. CROs & CDMOs
  • 8.5.3. Academic & Research Institutes
  • 8.5.4. Others
• 8.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.6.1. China
  • 8.6.2. Japan
  • 8.6.3. India
  • 8.6.4. Australia
  • 8.6.5. Southeast Asia
  • 8.6.6. Rest of Asia Pacific

9. Latin America Custom Antibody Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Service
  • 9.1.1. Antibody Design and Development
  • 9.1.2. Antibody Production & Purification
  • 9.1.3. Antibody Fragmentation & Labelling
  • 9.1.4. Others
• 9.2. Market Analysis, Insights and Forecast - By Antibody Type
  • 9.2.1. Monoclonal Antibodies (mAbs)
  • 9.2.2. Polyclonal Antibodies (pAbs)
  • 9.2.3. Recombinant Antibodies
  • 9.2.4. Others
• 9.3. Market Analysis, Insights and Forecast - By Source
  • 9.3.1. Mice
  • 9.3.2. Rabbit
  • 9.3.3. Others
• 9.4. Market Analysis, Insights and Forecast - By Application
  • 9.4.1. Therapeutics
  • 9.4.2. Diagnostics
  • 9.4.3. Research
• 9.5. Market Analysis, Insights and Forecast - By End User
  • 9.5.1. Pharmaceutical & Biotechnology Companies
  • 9.5.2. CROs & CDMOs
  • 9.5.3. Academic & Research Institutes
  • 9.5.4. Others
• 9.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.6.1. Brazil
  • 9.6.2. Mexico
  • 9.6.3. Rest of Latin America

10. Middle East & Africa Custom Antibody Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Service
  • 10.1.1. Antibody Design and Development
  • 10.1.2. Antibody Production & Purification
  • 10.1.3. Antibody Fragmentation & Labelling
  • 10.1.4. Others
• 10.2. Market Analysis, Insights and Forecast - By Antibody Type
  • 10.2.1. Monoclonal Antibodies (mAbs)
  • 10.2.2. Polyclonal Antibodies (pAbs)
  • 10.2.3. Recombinant Antibodies
  • 10.2.4. Others
• 10.3. Market Analysis, Insights and Forecast - By Source
  • 10.3.1. Mice
  • 10.3.2. Rabbit
  • 10.3.3. Others
• 10.4. Market Analysis, Insights and Forecast - By Application
  • 10.4.1. Therapeutics
  • 10.4.2. Diagnostics
  • 10.4.3. Research
• 10.5. Market Analysis, Insights and Forecast - By End User
  • 10.5.1. Pharmaceutical & Biotechnology Companies
  • 10.5.2. CROs & CDMOs
  • 10.5.3. Academic & Research Institutes
  • 10.5.4. Others
• 10.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.6.1. GCC
  • 10.6.2. South Africa
  • 10.6.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Thermo Fisher Scientific Inc.
  • 11.2.2. GenScript
  • 11.2.3. Bio Rad Laboratories, Inc.
  • 11.2.4. Danaher
  • 11.2.5. Enzo Life Sciences, Inc.
  • 11.2.6. R&D Systems, Inc.
  • 11.2.7. RayBiotech, Inc.
  • 11.2.8. ProteoGenix
  • 11.2.9. Vector Laboratories, Inc.
  • 11.2.10. Sino Biological, Inc.